In a groundbreaking study, researchers have unveiled an experimental medication that could revolutionize heart health by significantly lowering levels of lipoprotein(a), commonly referred to as Lp(a). This cholesterol-like particle has been linked to an increased risk of heart attacks and strokes, yet many remain unaware of its presence in their bloodstream. The Cleveland Clinic, which spearheaded the research, has dubbed elevated Lp(a) as “one of the last untreatable frontiers of cardiovascular risk.” This new development could change the game for millions.
Understanding lipoprotein(a) and its risks
Approximately 20-25% of the global population has elevated levels of Lp(a), translating to around 64 million individuals in the U.S. alone. Unlike low-density lipoprotein (LDL), often labeled as “bad cholesterol,” Lp(a) is more likely to contribute to plaque buildup and arterial clots. Dr. Steven Nissen, the study’s lead author, emphasizes that Lp(a) is an independent risk factor for heart disease, primarily determined by genetics. This means that lifestyle changes like diet and exercise, which can effectively lower LDL levels, have no impact on Lp(a) levels.
The breakthrough with lepodisiran
The experimental drug, lepodisiran, developed by Eli Lilly, works by silencing the gene responsible for synthesizing Lp(a). In a clinical trial involving 320 participants from various countries, those who received the highest dose of lepodisiran experienced a nearly 100% reduction in Lp(a) levels within six months. This remarkable finding suggests that the therapy could effectively eliminate Lp(a) from the bloodstream, offering hope to those at risk of cardiovascular diseases.
Implications for future heart health
While the results are promising, experts caution that further research is necessary. The study did not conclusively demonstrate that lowering Lp(a) levels directly correlates with a reduced risk of heart attacks or strokes. Dr. Deepak L. Bhatt, a prominent cardiologist, stresses the need for a phase 3 trial to explore the clinical impacts of this drug. Additionally, the current study had limitations, including a lack of diversity among participants and the need for more extensive dosing trials.
Despite these challenges, the findings are a significant step forward in understanding and treating elevated Lp(a). Cardiologists recommend that all adults check their Lp(a) levels at least once in their lifetime, as these levels remain stable throughout life. With the potential for a new treatment on the horizon, individuals with elevated Lp(a) may soon have options to manage their heart health more effectively.
